Drug intelligence / Profile preview

honokiol liposome for injection

Development stage: Unknown
Lead developer: Chengdu Jinruijiye Biotechnology
Modality: Small Molecules
Administration: Intravenous

Overview

Honokiol liposome for injection (JRF101) is an innovative liposomal formulation of honokiol, a natural biphenyl compound extracted from Magnolia officinalis. Developed by Jinrui Foundation Biotech, it is designed to improve the solubility, bioavailability, and tumor-targeting capability of honokiol. The drug acts as a direct inhibitor of the oncogenic transcription factor Forkhead box protein M1 (FOXM1), disrupting its transcriptional activity and downregulating its expression. This leads to the suppression of tumor cell proliferation, migration, and survival, and helps overcome resistance to chemotherapy and targeted therapies. JRF101 is currently in Phase II clinical trials for glioblastoma and Phase I trials for other advanced malignant solid tumors, and has received Orphan Drug Designation from the FDA.

Other names: honokiol liposomehonokiol liposome lyophilized powder for injection和厚朴酚脂质体注射用和厚朴酚脂质体

Targets

TXNRD2 (Thioredoxin reductase 2)SHH (Sonic hedgehog)HSPB1 (Heat shock protein beta-1)PK (Pyruvate kinase)FOXM1 (Forkhead box protein M1)Hsp70 (70 kDa heat shock protein)

Beyond the preview

Go deeper on honokiol liposome for injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on honokiol liposome for injection.

Explore the full profile